Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering

Ironwood Pharmaceuticals, Inc. (Ironwood) (Nasdaq: IRWD), a GI-focused healthcare company, today announced the pricing of $175 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2024 (the 2024 Notes) and $175 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2026 (the 2026 Notes and, together with the 2024 Notes, the Notes).